Prostate intraepithelial neoplasia in Noble rats, a potential intermediate endpoint for chemoprevention studies.
In most prostate chemoprevention studies conducted with animal models, the incidence and multiplicity of tumours have been used as endpoints for efficacy. However, the latency of tumours is usually over 1 year, making these studies costly and time consuming. The main purpose of this study was to assess the utility of prostate intraepithelial neoplasia (PIN), induced in Noble rats by continuous testosterone + oestradiol (T + E) administration, as a potential intermediate endpoint biomarker of efficacy in chemoprevention studies. Noble rats at the age of 12 weeks were treated for 36 weeks with T + E given subcutaneously via Silastic capsules. The incidence and multiplicity of PIN were assessed in various prostate glands by serial sections generated at three separate tissue levels. The efficacy of dehydroepiandrosterone (DHEA) and DHEA 8354 (1000 and 2000 mg/kg diet), difluoromethylornithine (DFMO) (1000 and 2000 mg/kg diet) and oltipraz (125 and 250 mg/kg diet) to inhibit PIN was assessed in two independent sets of experiments. T + E induced multiple PIN in the dorsolateral prostate (DLP) of 80-100% of the animals. DHEA and DHEA 8354 did not affect the incidence but decreased the multiplicity of PIN in the DLP, from 3.2 +/- 1.0 in control group to 1.5 +/- 1.0 in the low-dose and to 1.6 +/- 0.6 in the high-dose group for DHEA (P<0.05 and P<0.02, respectively), and to 1.9 +/- 0.8 in the high-dose (P<0.05) DHEA 8354. Both agents did not affect PIN in anterior prostate, seminal vesicles or ventral prostate. In a second experiment, DFMO and oltipraz were found not effective in inhibiting PIN. In this study, we provide new evidence that PIN in Noble rats, induced by continuous T + E treatment, is a useful intermediate endpoint for determining the efficacy of DHEA and other potential chemopreventive agents. The hormonal pathogenesis, high multiplicity, short latency, preferential location in the DLP, similarity in morphology and biology to PIN of human prostate, and the sensitivity to agents that suppress prostate carcinogenesis, makes PIN in Noble rats a promising intermediate endpoint for chemoprevention studies.
Christov
K T
KT
Department of Surgical Oncology Laboratories, University of Illinois, 840 South Wood Str., MC 820, Chicago, IL 60612, USA. christov@uic.edu
Moon
R C
RC
Lantvit
D D
DD
Boone
C W
CW
Kelloff
G J
GJ
Steele
V E
VE
Lubet
R A
RA
Pezzuto
J M
JM
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use; D003687:Dehydroepiandrosterone / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004354:Drug Screening Assays, Antitumor; D000518:Eflornithine / Q000627:therapeutic use; D004958:Estradiol; D008297:Male; D023421:Models, Animal; D019048:Prostatic Intraepithelial Neoplasia / Q000139:chemically induced / Q000188:drug therapy / Q000473:pathology; D011471:Prostatic Neoplasms / Q000139:chemically induced / Q000188:drug therapy / Q000473:pathology; D011719:Pyrazines / Q000627:therapeutic use; D051381:Rats; D011919:Rats, Inbred Strains; D013739:Testosterone; D013871:Thiones; D013876:Thiophenes; D013997:Time Factors
D000970:Antineoplastic Agents; D011719:Pyrazines; D013871:Thiones; D013876:Thiophenes; D013739:Testosterone; D003687:Dehydroepiandrosterone; D004958:Estradiol; C026209:oltipraz; C106219:5-androstene-16-fluoro-17-one; D000518:Eflornithine